ReviewInfectious disease clinics of North America2004
Antimicrobial therapy of community-acquired pneumonia.
Review in Infectious disease clinics of North America, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01661920 (Suitability of Antibiotic Treatment for Community-acquired Pneumonia), which is not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Suitability of Antibiotic Treatment for Community-acquired Pneumonia
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Short-course versus long-course therapy of the same antibiotic for community-acquired pneumonia in adolescent and adult outpatients.The Cochrane database of systematic reviews · 2018Pooled it
- Clinical Outcomes Associated with Oral Versus Intravenous Antibiotic Therapy in Emergency Department-Discharged Patients with Community-Acquired Pneumonia.Journal of clinical medicine · 2025Article
- Effects of community-acquired pneumonia on biventricular cardiac functions in children.Italian journal of pediatrics · 2025Article
- Treatment of lung diseasesMaterials today. Bio · 2025Review
- Real-world efficacy and safety of cefepime for pediatric community-acquired pneumonia: a propensity score-matched study.Frontiers in cellular and infection microbiology · 2025Article
- Profiles of oral microbiome associated with nasogastric tube feeding.Journal of oral microbiology · 2023Article
- Antibacterial and anti-biofilm activity of plumbagin against multi-drug resistant clinical bacterial isolates.Saudi medical journal · 2022Article
- Update on new research in Gram-negative infections European Congress of Clinical Microbiology and Infectious Diseases 2017 (22-25 April, Vienna, Austria).Future science OA · 2018Article
- New diagnostic tests for pneumonia: what is their role in clinical practice?Clinics in chest medicine · 2011Review
- Treatment of community-acquired pneumonia, with special emphasis on gemifloxacin.Therapeutics and clinical risk management · 2007Article
- Nursing home-acquired pneumonia: update on treatment options.Drugs & aging · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Community-acquired pneumonia (CAP) is a common disorder that is potentially life-threatening, especially in older adults and patients with comorbid disease. Despite substantial progress in therapeutic options, CAP remains a primary cause of death from infectious disease in the United States. The mainstay of treatment for most patients is appropriate antimicrobial therapy This article reviews the principles for initial antimicrobial therapy, highlights some of the differences in approaches to antimicrobial drug selection in selected guidelines, and includes new recommendations for empiric and pathogen-directed therapy of CAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.